Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + SOX
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
sintilimab + SOX is a combination therapy used primarily in the treatment of advanced or locally advanced gastric cancer. It consists of sintilimab, a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor (monoclonal antibody), and the SOX chemotherapy regimen. The SOX regimen includes S-1 (an oral fluoropyrimidine: a combination of tegafur, gimeracil, and oteracil) and oxaliplatin (a platinum-based chemotherapeutic). This combination is being evaluated in perioperative and first-line settings for gastric cancer, showing higher pathological response rates compared to chemotherapy alone in several clinical trials. The mechanism of action relies on both direct cytotoxic effects (via oxaliplatin and S-1) and immune-mediated anti-tumor activity (via sintilimab targeting PD-1, restoring T-cell mediated cancer cell killing)[1][3][4][9].
- Brand names
- Tyvyt
- Other names
- sintilimab plus SOXsintilimab combined with SOX
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on sintilimab + SOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + SOX.